IT HAS ALREADY BEEN A EVENTFUL WEEK FOR 
TNXP WITH CAPITAL RAISE ISSUES AND A NEW PIPELINE DRUG CANDIDATE UPDATE. NEST WEEK COULD BE EQUALLY IMPORTANT AS ON TUESDAY THE COMPANY RELEASES DATA ON TNX-102 PHARMACOKINTEC . THE STOCK IS SETTING UP NICELY FOR THE WEEK TO COME.
COMPANY PROFILE
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which engages in discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. It focuses on delivering a safe and effective long-term treatment for posttraumatic stress disorder. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya.
TNXP WITH CAPITAL RAISE ISSUES AND A NEW PIPELINE DRUG CANDIDATE UPDATE. NEST WEEK COULD BE EQUALLY IMPORTANT AS ON TUESDAY THE COMPANY RELEASES DATA ON TNX-102 PHARMACOKINTEC . THE STOCK IS SETTING UP NICELY FOR THE WEEK TO COME.COMPANY PROFILE
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which engages in discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. It focuses on delivering a safe and effective long-term treatment for posttraumatic stress disorder. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.